TMCnet News
Traumatic Brain Injury - Pipeline Review, H1 2017 - Research and MarketsResearch and Markets has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2017" report to their offering. Pharmaceutical and Healthcare latest pipeline guide Traumatic Brain Injury - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Traumatic Brain Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Traumatic Brain Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 7, 3, 1, 56 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 11 and 1 molecules, respectively. Traumatic Brain Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market ad their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/wspw57/traumatic_brain
View source version on businesswire.com: http://www.businesswire.com/news/home/20170315005595/en/ |
